← Patent-cliff monitor small molecule XPOVIO SELINEXOR
Loss of exclusivity August 2035 latest FDA-listed patent expiry
Drug detail Brand name XPOVIO Active ingredient SELINEXOR Strength 50MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval April 2021 Marketing status RX
Listed patents Patent Expires Type 11746102 August 2035 use U-3018 11753401 August 2035 product 11807629 August 2035 substance, product 10519139 August 2035 substance, product 8999996 July 2033 substance, product 11034660 July 2032 use U-3018 9714226 July 2032 substance, product 12291508 July 2032 use U-2584 11787771 July 2032 use U-2584 9079865 July 2032 use U-2584 10544108 July 2032 use U-3018
Regulatory exclusivity Code Expires ODE* December 2027 ODE* June 2027 ODE* July 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.